Journal of NeurochemistryMay 1, 2026Jannik Nicklas Eliasen, Amir Rezagholizadeh, Helene Påbøl Jacobsen et al.
ABSTRACT Depression and substance use disorder (SUD) affect millions globally and unfortunately, while established treatments exist, they are not always adequate. Psychedelics have emerged as a promising avenue for development of more effective pharmacological interventions. Dimethyltryptamine (DMT), a classic psychedelic, has shown anti‐depressive and anti‐addictive properties in preclinical...
NeuroscienceOctober 5, 2025Jannik Nicklas Eliasen, Amir Rezagholizadeh, Helene Påbøl Jacobsen et al.1 citation
Depression and substance use disorder affect millions world-wide, and risk factors include sex. Conventional pharmacotherapies show at best a 50 % success rate. Psychedelics exhibit both anti-addictive and anti-depressive properties. One of these, ibogaine, a root bark sourced alkaloid, interacts with receptors implicated in anti-depressive and anti-addictive effects with affinities in the...